Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists... see more

Recent & Breaking News (NYSEAM:PTN)

Palatin Announces Intent to Effect Reverse Stock Split

PR Newswire August 19, 2022

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

PR Newswire August 16, 2022

Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter

PR Newswire July 26, 2022

Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

PR Newswire May 17, 2022

Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock

PR Newswire May 12, 2022

Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022

PR Newswire May 11, 2022

Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

PR Newswire May 2, 2022

Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

PR Newswire April 21, 2022

Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease

PR Newswire March 3, 2022

Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

PR Newswire February 15, 2022

Palatin to Report Second Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on February 15, 2022

PR Newswire February 10, 2022

Palatin Announces Presentation at the 2022 Crohn's and Colitis Congress

PR Newswire January 21, 2022

Palatin to Present at H.C. Wainwright BioConnect Conference

PR Newswire January 7, 2022

Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease

PR Newswire December 28, 2021

Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide

PR Newswire November 30, 2021

Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update

PR Newswire November 15, 2021

Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021

PR Newswire November 10, 2021

Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting

PR Newswire October 22, 2021

Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update

PR Newswire September 29, 2021

Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

PR Newswire September 27, 2021